SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/338386"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/338386" > The efficacy of imm...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006836naa a2201021 4500
001oai:gup.ub.gu.se/338386
003SwePub
008240608s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:150361679
009oai:prod.swepub.kib.ki.se:150961293
009oai:gup.ub.gu.se/322093
024a https://gup.ub.gu.se/publication/3383862 URI
024a https://doi.org/10.1016/j.ejca.2022.03.0412 DOI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1503616792 URI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1509612932 URI
024a https://gup.ub.gu.se/publication/3220932 URI
040 a (SwePub)gud (SwePub)kid (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Holmberg, Carl Jacobu Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Wallenberg Centre for Molecular and Translational Medicine,Sahlgrenska Center for Cancer Research (SCCR),Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery4 aut0 (Swepub:gu)xhocas
2451 0a The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study
264 1b Elsevier BV,c 2022
520 a Purpose: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials for exclusively ITM disease. The study aims to analyze the outcome of patients with ITM treated with ICI based on data from a large cohort of patients treated at international referral clinics. Methods: A multicenter retrospective cohort study of patients treated between January 2015 and December 2020 from Australia, Europe, and the USA, evaluating treatment with ICI for ITM with or without nodal involvement (AJCC8 N1c, N2c, and N3c) and without distant disease (M0). Treatment was with PD-1 inhibitor (nivolumab or pembrolizumab) and/or CTLA-4 inhibitor (ipilimumab). The response was evaluated according to the RECIST criteria modified for cutaneous lesions. Results: A total of 287 patients from 21 institutions in eight countries were included. Immunotherapy was first-line treatment in 64 (22%) patients. PD-1 or CTLA-4 inhibitor monotherapy was given in 233 (81%) and 23 (8%) patients, respectively, while 31 (11%) received both in combination. The overall response rate was 56%, complete response (CR) rate was 36%, and progressive disease (PD) rate was 32%. Median PFS was ten months (95% CI 7.4-12.6 months) with a one-, two-, and five-year PFS rate of 48%, 33%, and 18%, respectively. Median MSS was not reached, and the one-, two-, and five-year MSS rates were 95%, 83%, and 71%, respectively. Conclusion: Systemic immunotherapy is an effective treatment for melanoma ITM. Future studies should evaluate the role of systemic immunotherapy in the context of multimodality therapy, including locoregional treatments such as surgery, intralesional therapy, and regional therapies.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Melanoma
653 a In-transit metastasis
653 a Immune checkpoint inhibitor
653 a PD-1
653 a Nivolumab
653 a Pembrolizumab
653 a Ipilimumab
653 a Oncology
700a Ny, Lars,d 1967u Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Sahlgrenska Center for Cancer Research (SCCR),Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xnylai
700a Hieken, Tina J.4 aut
700a Block, Matthew S.4 aut
700a Carr, Michael J.4 aut
700a Sondak, Vernon K.4 aut
700a Ortenwall, Christoffer4 aut
700a Katsarelias, Dimitriosu Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Sahlgrenska Center for Cancer Research (SCCR)4 aut0 (Swepub:gu)xkatdi
700a Dimitriou, Florentia4 aut
700a Menzies, Alexander M.4 aut
700a Saw, Robyn P. M.4 aut
700a Rogiers, Aljosja4 aut
700a Straker, Richard J.4 aut
700a Karakousis, Giorgos4 aut
700a Applewaite, Rona4 aut
700a Pallan, Lalit4 aut
700a Han, Dale4 aut
700a Vetto, John T.4 aut
700a Gyorki, David E.4 aut
700a Tie, Emilia Nan4 aut
700a Vitale, Maria Grazia4 aut
700a Ascierto, Paulo A.4 aut
700a Dummer, Reinhard4 aut
700a Cohen, Jade4 aut
700a Hui, Jane Y. C.4 aut
700a Schachter, Jacob4 aut
700a Asher, Nethanel4 aut
700a Helgadottir, H.u Karolinska Institutet4 aut
700a Chai, Harvey4 aut
700a Kroon, Hidde4 aut
700a Coventry, Brendon4 aut
700a Rothermel, Luke D.4 aut
700a Sun, James4 aut
700a Carlino, Matteo S.4 aut
700a Duncan, Zoey4 aut
700a Broman, Kristy4 aut
700a Weber, Jeffrey4 aut
700a Lee, Ann Y.4 aut
700a Berman, Russell S.4 aut
700a Teras, Juri4 aut
700a Ollila, David W.4 aut
700a Long, Georgina4 aut
700a Zager, Jonathan S.4 aut
700a van Akkooi, Alexander4 aut
700a Olofsson Bagge, Roger,d 1978u Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Wallenberg Centre for Molecular and Translational Medicine,Sahlgrenska Center for Cancer Research (SCCR),Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery4 aut0 (Swepub:gu)xoloro
700a I. TforIT Res Collaboration, I. TforIT Res Collaboration4 aut
710a Göteborgs universitetb Sahlgrenska Centrum för Cancerforskning (SCCR)4 org
773t EUROPEAN JOURNAL OF CANCERd : Elsevier BVg 40:16q 169<210-222x 0959-8049x 1879-0852
773t JOURNAL OF CLINICAL ONCOLOGYd : Elsevier BVg 40:16q 40:16x 0732-183Xx 1527-7755
8564 8u https://gup.ub.gu.se/publication/338386
8564 8u https://doi.org/10.1016/j.ejca.2022.03.041
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:150361679
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:150961293
8564 8u https://gup.ub.gu.se/publication/322093

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy